William Blair & Company
ACHN

William Blair & Company’s Achillion Pharmaceuticals ACHN Stock Holding History

William Blair & Company’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37,000
Closed -$133K – 1831
2019
Q3 		$133K Sell
37,000
-100
-0.3% -$386 ﹤0.01% 1347
2019
Q2 		$99K Sell
37,100
-18,500
-33% -$54.6K ﹤0.01% 1425
2019
Q1 		$165K Buy
55,600
+1,000
+2% +$2.46K ﹤0.01% 1339
2018
Q4 		$87K Sell
54,600
-2,300
-4% -$6.5K ﹤0.01% 1338
2018
Q3 		$209K Buy
56,900
+1,000
+2% +$2.98K ﹤0.01% 1278
2018
Q2 		$158K Buy
55,900
+400
+0.7% +$1.36K ﹤0.01% 1297
2018
Q1 		$206K Hold
55,500
– – ﹤0.01% 1198
2017
Q4 		$160K Buy
55,500
+100
+0.2% +$363 ﹤0.01% 1285
2017
Q3 		$249K Sell
55,400
-6,800
-11% -$30.2K ﹤0.01% 1187
2017
Q2 		$285K Buy
62,200
+22,800
+58% +$91.6K ﹤0.01% 1214
2017
Q1 		$158K Sell
39,400
-3,000
-7% -$12.5K ﹤0.01% 1256
2016
Q4 		$175K Buy
42,400
+3,500
+9% +$18.6K ﹤0.01% 1172
2016
Q3 		$315K Buy
38,900
+1,500
+4% +$12.8K ﹤0.01% 1004
2016
Q2 		$292K Sell
37,400
-25,900
-41% -$222K ﹤0.01% 993
2016
Q1 		$488K Buy
63,300
+22,900
+57% +$168K ﹤0.01% 799
2015
Q4 		$435K Sell
40,400
-35,600
-47% -$324K ﹤0.01% 849
2015
Q3 		$525K Sell
76,000
-71,630
-49% -$584K ﹤0.01% 960
2015
Q2 		$1.31M Buy
147,630
+103,130
+232% +$975K ﹤0.01% 1497
2015
Q1 		$438K Buy
44,500
+29,500
+197% +$368K ﹤0.01% 1752
2014
Q4 		$183K Buy
15,000
+3,000
+25% +$36.6K ﹤0.01% 1978
2014
Q3 		$119K Buy
+12,000
New +$111K ﹤0.01% 2011
2014
Q2 		– Sell
-16,800
Closed -$55K – 2132
2014
Q1 		$55K Buy
16,800
+700
+4% +$2.45K ﹤0.01% 1979
2013
Q4 		$53K Sell
16,100
-1,400
-8% -$4.06K ﹤0.01% 1948
2013
Q3 		$52K Hold
17,500
– – ﹤0.01% 1985
2013
Q2 		$143K Buy
+17,500
New +$134K ﹤0.01% 1858

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's ACHN Position: Q4 2019 in Review

William Blair & Company sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 37,000 shares — an estimated $133K sold.

William Blair & Company first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $1.31M in Q2 2015. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • William Blair & Company reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • William Blair & Company sold 37,000 Achillion Pharmaceuticals shares in Q4 2019, an estimated $133K.
  • William Blair & Company first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • William Blair & Company's Achillion Pharmaceuticals position peaked at $1.31M in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on William Blair & Company's 13F filing for Q4 2019, filed 13 Feb 2020.